Mutant p53 protein in the serum of patients with cervical carcinoma: Correlation with the level of serum epidermal growth factor receptor and prognostic significance

Cancer Letters

Volumn 203, Issue 1, 2004, Pages 107-112

  Oh, Min Jeong ^a   Choi, Jin Hyuk ^b   Lee, Yong Ho ^a   Lee, Jae Kwan ^a   Hur, Joon Young ^a   Park, Yong Kyun ^a   Lee, Kyu Wan ^a   Chough, Soo Yong ^a   Saw, Ho Suk ^a  

^a Korea University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Cervical carcinoma; Epidermal growth factor receptor; Mutant p53; Prognosis; Serum

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOACCUMULATION; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INVASIVE CARCINOMA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT CANCER; UTERINE CERVIX CARCINOMA;

EID: 0344737000     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.09.025     Document Type: Article

References (30)

1. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1993;1318-1327.
2. Helland A., Holm R., Kristensen G., Kaern J., Karlsen F., Trope C., et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J. Pathol. 171:1993;105-114.
3. Kersemaekers A.-M.F., Fleuren G.J., Kenter G.G., Van den Broek L.J.C.M., Uljee S.M., Hermans J., Van de Vijver M.J. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 5:1999;577-586.
4. Skomedal H., Kristensen G.B., Lie A.K., Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 73:1999;223-228.
5. Dimitrakakis C., Kymionis G., Diakomanolis E., Papaspyrou I., Rodolakis A., Arzimanoglou I., et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol. Oncol. 77:2000;129-136.
6. Oka K., Suzuki Y., Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer. 88:2000;2766-2773.
7. Chen H.Y., Hsu C.T., Lin W.C., Tsai H.D., Chang W.C. Prognostic value of p53 expression in stage IB1 cervical carcinoma. Gynecol. Obstet. Invest. 49:2000;266-271.
8. Horn L.C., Fischer U., Hanel C., Kuhn H., Raptis G., Bilek K. p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread. Pathol. Res. Pract. 197:2001;605-609.
9. Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., Lee T.T. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol. Oncol. 83:2001;348-354.
10. Brenna S.M., Zeferino L.C., Pinto G.A., Souza R.A., Andrade L.A., Vassalo J., et al. P53 expression as a predictor of recurrence in cervical squamous cell carcinoma. Int. J. Gynecol Cancer. 12:2002;299-303.
11. Luo J.-C., Zehab R., Anttila S., Ridanpaa M., Husgafvel-Pursiainen K., Vainio H., et al. Detection of serum p53 protein in lung cancer patients. J. Occup. Med. 36:1994;155-160.
12. Partanen R., Koskinen H., Oksa P., Hemminki K., Carney W., Smith S., Brandt-Rauf P. Serum oncoproteins in asbestosis patients. Clin. Chem. 41:1995;1844-1847.
13. Osaki T., Mitsudomi T., Oyama T., Nakanishi R., Yasumoto K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest. 108:1995;157-162.
14. Choi J.-H., Oh J.Y., Ryu S.K., Kim S.J., Lee N.Y., Kim Y.S., et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer. 79:1997;1879-1883.
15. Oh M.J., Choi J.-H., Kim I.H., Lee Y.H., Huh J.Y., Park Y.K., et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin. Cancer Res. 6:2000;4760-4763.
16. Shepherd J.H. Staging announcement. FIGO staging of gynecologic cancers; cervical and vulva. Int. J. Gynecol. Cancer. 5:1995;319.
17. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Statist. Assoc. 53:1958;457-481.
18. Cox D.R. Regression models and life tables. J. R. Statist. Soc. 34:1972;187-220.
19. Sobti R.C., Parashar K., Kaur R., Capalash N. Detection of human papillomavirus DNA, serum p53, and p53 antibodies in patients with cervical cancer. J. Environ. Pathol. Toxicol. Oncol. 21:2002;79-85.
20. Angelopoulou K., Diamandis E.P., Sutherland D.J.A., Kellen J.A., Bunting P.S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer. 58:1994;480-487.
21. Deb S.P., Munoz R.M., Brown D.R., Subler M.A., Deb S. human p53 activates the human epidermal growth factor receptor promoter. Oncogene. 9:1994;1341-1349.
22. Ludes-Meyers J.H., Subler M.A., Shivakumar C.V., Munoz R.M., Jiang P., Bigger J.E., et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell Biol. 16:1996;6009-6019.
23. Sheikh M.S., Carrier F., Johnson A.C., Ogdon S.E., Fornace A.J. Jr. Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor. Oncogene. 15:1997;1095-1101.
24. Esteve A., Lehman T., Jiang W., Weinstein I.B., Harris C.C., Ruol A., et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol. Carcinog. 8:1993;306-311.
25. Chen B.K., Ohtsuki Y., Furihata M., Takeuchi T., Iwata J., Liang S.B., Sonobe H. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int. J. Oncol. 15:1999;893-898.
26. Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Meier W., Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 33:1989;146-150.
27. Berchuck A., Rodriguez G., Kamel A., Soper J.T., Clarke-Pearson D.L., Bast R.C. Jr. Expression of epidermal growth factor receptor and HER-2/Neu in normal and neoplastic cervix, vulva, and vagina. Obstet. Gynecol. 76:1990;381-387.
28. Scambia G., Ferrandina G., Distefano M., D'Agostino G., Benedetti-Panici P., Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 123:1998;135-139.
29. Kristensen G.B., Holm R., Abeler V.M., Trope C.G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma: an immunohistochemical study. Cancer. 78:1996;433-440.
30. Kim Y.T., Park S.W., Kim J.W. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol. Oncol. 87:2002;84-89.